Device Trial Radar · NCT02372877
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Last checked: Nov 19, 2026Latest source record: Jul 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
May 2015
Primary completion
Dec 7, 2017
Study completion Jan 19, 2018
Sponsor
- Lead sponsor
- Fenwal, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Versiti Blood Health; Children's Hospital of Philadelphia; Barbara Ann Karmanos Cancer Institute; University of Texas; Washington University School of Medicine; Phoenix Children's Hospital
- First posted
- Feb 26, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the performance of the AMICUS Red Blood Cell Exchange (RBCx) System (Exchange and Depletion/Exchange procedures) in patients with sickle cell disease.
Conditions
- Sickle Cell Anemia
Interventions
Amicus Red Cell Exchange in SCD patientsDevice
Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Actual Fraction of Original Red Blood Cells Remaining to the Target Fraction of Cells Remaining (FCR).Time frame: Actual FCR will be assessed by taking a pre-procedure sample from the patient on the day of the procedure and a post-procedure sample approximately 10-15 min after procedure completion.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Washington University
St Louis, Missouri
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.